Assenagon Asset Management S.A. Grows Holdings in Illumina, Inc. $ILMN

Key Points

• Assenagon Asset Management increased its Illumina stake by 188.6% in the second quarter, ending with 140,003 shares valued at approximately $24.6 million. Institutional investors collectively own 89.42% of the company.
• Illumina exceeded quarterly expectations with EPS of $1.31 versus $1.23 estimated and revenue of $1.16 billion, up 9.4% year over year. The company maintained fiscal 2026 EPS guidance of $5.30 to $5.40.
• Analyst sentiment remains mixed: the consensus rating is “Hold” with an average price target of $188.40, while insiders sold about $303.9 million of stock over the past 90 days.

Assenagon Asset Management S.A. lifted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 188.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 140,003 shares of the life sciences company's stock after acquiring an additional 91,495 shares during the quarter. Assenagon Asset Management S.A. owned 0.09% of Illumina worth $24,617,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ILMN. WCM Investment Management LLC lifted its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. Invesco Ltd. grew its stake in shares of Illumina by 97.0% in the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company's stock valued at $360,426,000 after buying an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company's stock valued at $580,531,000 after buying an additional 1,028,099 shares in the last quarter. Morgan Stanley raised its holdings in shares of Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company's stock valued at $331,710,000 after buying an additional 1,005,474 shares during the period. Finally, Vaughan Nelson Investment Management L.P. purchased a new stake in shares of Illumina in the 1st quarter valued at $106,462,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Insider Activity

In related news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 500 shares of the business's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares of the company's stock, valued at $2,311,360. This trade represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,744,811 shares of company stock worth $303,897,291 in the last ninety days. 2.90% of the stock is owned by insiders.

Illumina Stock Performance

ILMN opened at $187.96 on Monday. The business has a fifty day moving average price of $181.13 and a 200 day moving average price of $149.10. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $207.00. The stock has a market capitalization of $28.38 billion, a price-to-earnings ratio of 35.07, a PEG ratio of 2.65 and a beta of 1.44.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. TD Cowen raised their target price on Illumina from $192.00 to $210.00 and gave the company a "hold" rating in a report on Friday, July 31st. Citigroup boosted their price target on shares of Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a research note on Monday, August 3rd. Barclays increased their price target on shares of Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a "hold" rating in a research note on Wednesday. Finally, Leerink Partners lifted their price objective on shares of Illumina from $175.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Illumina presently has an average rating of "Hold" and an average target price of $188.40.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Zacks upgraded Illumina to Rank #1, or “Strong Buy,” citing improving earnings prospects and strong momentum characteristics. The upgrade could attract near-term buying interest. What Makes Illumina a New Strong Buy Stock
• Positive Sentiment: Illumina’s latest quarterly results provide a supportive backdrop: earnings per share exceeded estimates, revenue topped forecasts, and sales increased 9.4% year over year. The company continues to guide to fiscal 2026 EPS of $5.30 to $5.40. Recent bullish analysts have raised price targets as high as $230. Illumina Earnings and Analyst Information
• Neutral Sentiment: Analyst opinion remains divided. Although several firms maintain Buy or Outperform ratings, the consensus rating is “Hold,” with an average price target of $188.40—close to recent trading levels—suggesting limited consensus upside.
• Negative Sentiment: Director Keith A. Meister sold 741,127 shares across August 4 and 5 for approximately $148.2 million, reducing his position by about 28%. He retains more than 2 million shares, but the size of the transactions may pressure sentiment and raise concerns about insider confidence. Illumina Insider Trading Filing
• Negative Sentiment: Bank of America Securities reiterated its “Sell” rating and $140 price target, arguing that a one-time consumables benefit may be masking weak underlying demand. The target is well below recent levels, highlighting valuation and sustainability concerns. Bank of America Maintains Sell Rating

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source